59 related articles for article (PubMed ID: 29459439)
1. Apalutamide OK'd for Some Prostate Cancers.
Cancer Discov; 2018 Apr; 8(4):377. PubMed ID: 29459439
[TBL] [Abstract][Full Text] [Related]
2. Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies.
Alpajaro SIR; Harris JAK; Evans CP
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):16-23. PubMed ID: 30115959
[TBL] [Abstract][Full Text] [Related]
3. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
Dellis AE; Papatsoris AG
Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
[TBL] [Abstract][Full Text] [Related]
4. The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer.
Tripathy S
Indian J Urol; 2021; 37(3):293-294. PubMed ID: 34465966
[No Abstract] [Full Text] [Related]
5. First-Line Atezolizumab OK'd for SCLC.
Cancer Discov; 2019 May; 9(5):568-569. PubMed ID: 30910909
[TBL] [Abstract][Full Text] [Related]
6. Recent trends in the management of advanced prostate cancer.
Ritch C; Cookson M
F1000Res; 2018; 7():. PubMed ID: 30345007
[TBL] [Abstract][Full Text] [Related]
7. Filling a True Unmet Need: A New Therapy for Nonmetastatic Castrate-resistant Prostate Cancer Commentary on: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Kesch C; Black PC
Urology; 2018 Jun; 116():1-2. PubMed ID: 29596865
[No Abstract] [Full Text] [Related]
8. Pembrolizumab OK'd for Cervical Cancer.
Cancer Discov; 2018 Aug; 8(8):904. PubMed ID: 29967015
[TBL] [Abstract][Full Text] [Related]
9. Entrectinib OK'd for Cancers with
Cancer Discov; 2019 Oct; 9(10):OF2. PubMed ID: 31471291
[TBL] [Abstract][Full Text] [Related]
10. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
11. First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials.
Poorthuis MHF; Vernooij RWM; van Moorselaar RJA; de Reijke TM
BJU Int; 2017 Jun; 119(6):831-845. PubMed ID: 28063195
[TBL] [Abstract][Full Text] [Related]
12. First PARP Inhibitor Ok'd for Breast Cancer.
Cancer Discov; 2018 Mar; 8(3):256-257. PubMed ID: 29382645
[TBL] [Abstract][Full Text] [Related]
13. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.
Rathkopf DE; Antonarakis ES; Shore ND; Tutrone RF; Alumkal JJ; Ryan CJ; Saleh M; Hauke RJ; Bandekar R; Maneval EC; de Boer CJ; Yu MK; Scher HI
Clin Cancer Res; 2017 Jul; 23(14):3544-3551. PubMed ID: 28213364
[No Abstract] [Full Text] [Related]
14. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
15. First Comprehensive Companion Diagnostic OK'd.
Cancer Discov; 2018 Mar; 8(3):OF4. PubMed ID: 29339360
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapeutic OK'd for Neuroendocrine Tumors.
Cancer Discov; 2018 Oct; 8(10):1200-1201. PubMed ID: 30120112
[TBL] [Abstract][Full Text] [Related]
17. Amivantamab OK'd for
Cancer Discov; 2021 Jul; 11(7):1604. PubMed ID: 34083225
[TBL] [Abstract][Full Text] [Related]
18. Larotrectinib OK'd for Cancers with
Cancer Discov; 2019 Jan; 9(1):8-9. PubMed ID: 30510115
[TBL] [Abstract][Full Text] [Related]
19. The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer.
De Santis M; Steuber T
ESMO Open; 2019; 4(2):e000484. PubMed ID: 31231560
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
